skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: GRL-09510, a Unique P2-Crown-Tetrahydrofuranylurethane -Containing HIV-1 Protease Inhibitor, Maintains Its Favorable Antiviral Activity against Highly-Drug-Resistant HIV-1 Variants in vitro

Abstract

We report that GRL-09510, a novel HIV-1 protease inhibitor (PI) containing a newly-generated P2-crown-tetrahydrofuranylurethane (Crwn-THF), a P2'-methoxybenzene, and a sulfonamide isostere, is highly active against laboratory and primary clinical HIV-1 isolates (EC50: 0.0014–0.0028 μM) with minimal cytotoxicity (CC50: 39.0 μM). Similarly, GRL-09510 efficiently blocked the replication of HIV-1NL4-3 variants, which were capable of propagating at high-concentrations of atazanavir, lopinavir, and amprenavir (APV). GRL-09510 was also potent against multi-drug-resistant clinical HIV-1 variants and HIV-2ROD. Under the selection condition, where HIV-1NL4-3 rapidly acquired significant resistance to APV, an integrase inhibitor raltegravir, and a GRL-09510 congener (GRL-09610), no variants highly resistant against GRL-09510 emerged over long-term in vitro passage of the virus. Crystallographic analysis demonstrated that the Crwn-THF moiety of GRL-09510 forms strong hydrogen-bond-interactions with HIV-1 protease (PR) active-site amino acids and is bulkier with a larger contact surface, making greater van der Waals contacts with PR than the bis-THF moiety of darunavir. The present data demonstrate that GRL-09510 has favorable features for treating patients infected with wild-type and/or multi-drug-resistant HIV-1 variants, that the newly generated P2-Crwn-THF moiety confers highly desirable anti-HIV-1 potency. The use of the novel Crwn-THF moiety sheds lights in the design of novel PIs.

Authors:
; ; ; ; ; ; ;
Publication Date:
Research Org.:
Argonne National Lab. (ANL), Argonne, IL (United States). Advanced Photon Source (APS)
Sponsoring Org.:
USDOE
OSTI Identifier:
1397284
Resource Type:
Journal Article
Journal Name:
Scientific Reports
Additional Journal Information:
Journal Volume: 7; Journal Issue: 1; Journal ID: ISSN 2045-2322
Publisher:
Nature Publishing Group
Country of Publication:
United States
Language:
ENGLISH
Subject:
60 APPLIED LIFE SCIENCES

Citation Formats

Amano, Masayuki, Miguel Salcedo-Gómez, Pedro, Yedidi, Ravikiran S., Delino, Nicole S., Nakata, Hirotomo, Venkateswara Rao, Kalapala, Ghosh, Arun K., and Mitsuya, Hiroaki. GRL-09510, a Unique P2-Crown-Tetrahydrofuranylurethane -Containing HIV-1 Protease Inhibitor, Maintains Its Favorable Antiviral Activity against Highly-Drug-Resistant HIV-1 Variants in vitro. United States: N. p., 2017. Web. doi:10.1038/s41598-017-12052-9.
Amano, Masayuki, Miguel Salcedo-Gómez, Pedro, Yedidi, Ravikiran S., Delino, Nicole S., Nakata, Hirotomo, Venkateswara Rao, Kalapala, Ghosh, Arun K., & Mitsuya, Hiroaki. GRL-09510, a Unique P2-Crown-Tetrahydrofuranylurethane -Containing HIV-1 Protease Inhibitor, Maintains Its Favorable Antiviral Activity against Highly-Drug-Resistant HIV-1 Variants in vitro. United States. doi:10.1038/s41598-017-12052-9.
Amano, Masayuki, Miguel Salcedo-Gómez, Pedro, Yedidi, Ravikiran S., Delino, Nicole S., Nakata, Hirotomo, Venkateswara Rao, Kalapala, Ghosh, Arun K., and Mitsuya, Hiroaki. Mon . "GRL-09510, a Unique P2-Crown-Tetrahydrofuranylurethane -Containing HIV-1 Protease Inhibitor, Maintains Its Favorable Antiviral Activity against Highly-Drug-Resistant HIV-1 Variants in vitro". United States. doi:10.1038/s41598-017-12052-9.
@article{osti_1397284,
title = {GRL-09510, a Unique P2-Crown-Tetrahydrofuranylurethane -Containing HIV-1 Protease Inhibitor, Maintains Its Favorable Antiviral Activity against Highly-Drug-Resistant HIV-1 Variants in vitro},
author = {Amano, Masayuki and Miguel Salcedo-Gómez, Pedro and Yedidi, Ravikiran S. and Delino, Nicole S. and Nakata, Hirotomo and Venkateswara Rao, Kalapala and Ghosh, Arun K. and Mitsuya, Hiroaki},
abstractNote = {We report that GRL-09510, a novel HIV-1 protease inhibitor (PI) containing a newly-generated P2-crown-tetrahydrofuranylurethane (Crwn-THF), a P2'-methoxybenzene, and a sulfonamide isostere, is highly active against laboratory and primary clinical HIV-1 isolates (EC50: 0.0014–0.0028 μM) with minimal cytotoxicity (CC50: 39.0 μM). Similarly, GRL-09510 efficiently blocked the replication of HIV-1NL4-3 variants, which were capable of propagating at high-concentrations of atazanavir, lopinavir, and amprenavir (APV). GRL-09510 was also potent against multi-drug-resistant clinical HIV-1 variants and HIV-2ROD. Under the selection condition, where HIV-1NL4-3 rapidly acquired significant resistance to APV, an integrase inhibitor raltegravir, and a GRL-09510 congener (GRL-09610), no variants highly resistant against GRL-09510 emerged over long-term in vitro passage of the virus. Crystallographic analysis demonstrated that the Crwn-THF moiety of GRL-09510 forms strong hydrogen-bond-interactions with HIV-1 protease (PR) active-site amino acids and is bulkier with a larger contact surface, making greater van der Waals contacts with PR than the bis-THF moiety of darunavir. The present data demonstrate that GRL-09510 has favorable features for treating patients infected with wild-type and/or multi-drug-resistant HIV-1 variants, that the newly generated P2-Crwn-THF moiety confers highly desirable anti-HIV-1 potency. The use of the novel Crwn-THF moiety sheds lights in the design of novel PIs.},
doi = {10.1038/s41598-017-12052-9},
journal = {Scientific Reports},
issn = {2045-2322},
number = 1,
volume = 7,
place = {United States},
year = {2017},
month = {9}
}

Works referenced in this record:

Improved survival in HIV-infected persons: consequences and perspectives
journal, July 2007

  • Lohse, Nicolai; Hansen, Ann-Brit Eg; Gerstoft, Jan
  • Journal of Antimicrobial Chemotherapy, Vol. 60, Issue 3
  • DOI: 10.1093/jac/dkm241

Refinement of Macromolecular Structures by the Maximum-Likelihood Method
journal, May 1997

  • Murshudov, G. N.; Vagin, A. A.; Dodson, E. J.
  • Acta Crystallographica Section D Biological Crystallography, Vol. 53, Issue 3
  • DOI: 10.1107/S0907444996012255

Overview of the CCP 4 suite and current developments
journal, March 2011

  • Winn, Martyn D.; Ballard, Charles C.; Cowtan, Kevin D.
  • Acta Crystallographica Section D Biological Crystallography, Vol. 67, Issue 4
  • DOI: 10.1107/S0907444910045749

Nine Crystal Structures Determine the Substrate Envelope of the MDR HIV-1 Protease
journal, March 2011


HIV-associated neurocognitive disorder — pathogenesis and prospects for treatment
journal, March 2016

  • Saylor, Deanna; Dickens, Alex M.; Sacktor, Ned
  • Nature Reviews Neurology, Vol. 12, Issue 4
  • DOI: 10.1038/nrneurol.2016.27

PHENIX: a comprehensive Python-based system for macromolecular structure solution
journal, January 2010

  • Adams, Paul D.; Afonine, Pavel V.; Bunkóczi, Gábor
  • Acta Crystallographica Section D Biological Crystallography, Vol. 66, Issue 2, p. 213-221
  • DOI: 10.1107/S0907444909052925

P2′ Benzene Carboxylic Acid Moiety Is Associated with Decrease in Cellular Uptake: Evaluation of Novel Nonpeptidic HIV-1 Protease Inhibitors Containing P2 bis -Tetrahydrofuran Moiety
journal, July 2013

  • Yedidi, Ravikiran S.; Maeda, Kenji; Fyvie, W. Sean
  • Antimicrobial Agents and Chemotherapy, Vol. 57, Issue 10
  • DOI: 10.1128/AAC.00868-13

electronic Ligand Builder and Optimization Workbench ( eLBOW ): a tool for ligand coordinate and restraint generation
journal, September 2009

  • Moriarty, Nigel W.; Grosse-Kunstleve, Ralf W.; Adams, Paul D.
  • Acta Crystallographica Section D Biological Crystallography, Vol. 65, Issue 10
  • DOI: 10.1107/S0907444909029436

Stereoselective Photochemical 1,3-Dioxolane Addition to 5- Alkoxymethyl-2(5 H )-furanone:  Synthesis of Bis-tetrahydrofuranyl Ligand for HIV Protease Inhibitor UIC-94017 (TMC-114)
journal, November 2004

  • Ghosh, Arun K.; Leshchenko, Sofiya; Noetzel, Marcus
  • The Journal of Organic Chemistry, Vol. 69, Issue 23
  • DOI: 10.1021/jo049156y

MOLREP an Automated Program for Molecular Replacement
journal, December 1997